
- /
- Supported exchanges
- / US
- / MGX.NASDAQ
Metagenomi, Inc. Common Stock (MGX NASDAQ) stock market data APIs
Metagenomi, Inc. Common Stock Financial Data Overview
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Metagenomi, Inc. Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Metagenomi, Inc. Common Stock data using free add-ons & libraries
Get Metagenomi, Inc. Common Stock Fundamental Data
Metagenomi, Inc. Common Stock Fundamental data includes:
- Net Revenue: 33 768 K
- EBITDA: -86 295 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.72
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Metagenomi, Inc. Common Stock News

Databricks projects $4 billion in annual revenue on surging AI demand
(Reuters) -Analytics firm Databricks (DATB.PVT) was on track to hit $4 billion in annual revenue, up more than 50% from the prior year, on the back of surging demand for its AI products. In the secon...


Earnings call transcript: Mount Gibson Iron Q4 2025 highlights strategic shift
Mount Gibson Iron Ltd (MGX) reported its Q4 2025 earnings, showcasing a strategic pivot towards diversification and growth despite the absence of earnings forecasts. The company’s shares rose by 5.3...

Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected
METAGENOMI INC (NASDAQ:MGX [https://www.chartmill.com/stock/quote/MGX]) REPORTS Q2 2025 EARNINGS: REVENUE BEATS ESTIMATES, LOSS NARROWS Metagenomi Inc, a precision genetic medicines company, reported...

Metagenomi (MGX) Presents Latest in Gene Editing Technologies
Metagenomi, Inc. (NASDAQ:MGX) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 14, Metagenomi, Inc. (NASDAQ:MGX) announced that it is presenting three abstracts at the American Society ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.